[Nibentan -- a drug for pharmacological cardioversion of persistent atrial fibrillation].
OBJECTIVE
To assess efficacy of a potassium channel blocker nibentan for pharmacological cardioversion of persistent atrial fibrillation. Method. Nibentan (1% solution) was infused intravenously after 3 weeks of warfarin pretreatment to 31 patients with duration of atrial fibrillation from 4 weeks to 15 months.


RESULTS
Sinus rhythm was restored in 24 patients. Mean dose of nibentan was 0.119+/-0.02 mg/kg. Proarrhythmic effects (paroxysmal or nonsustained polymorphic ventricular tachycardia) and substantial suppression of sinus rhythm automatism were registered in 3 and 3 patients, respectively.


CONCLUSIONS
Nibentan is highly effective in persistent atrial fibrillation. It can be recommended for inhospital use in intensive care facilities.
Shubik
Iu V
IuV
Medvedev
M M
MM
Rivin
A E
AE
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000503:physiopathology; D001549:Benzamides / Q000008:administration & dosage / Q000627:therapeutic use*; D004562:Electrocardiography; D005260:Female; D005500:Follow-Up Studies; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
D001549:Benzamides; C105049:nibentan